Arvinas

Yale University scientist and entrepreneur Craig M. Crews has been named the inaugural recipient of the Yale Founders Award.

Arvinas turns its first FDA drug approval into a potentially lucrative licensing deal.

A long-in-development breast cancer drug gives Arvinas its first commercial foothold.

New Haven-based Arvinas Inc. on Thursday named longtime executive Randy Teel as its new president and chief executive officer, succeeding John Houston, who is retiring after nearly a decade leading the biotechnology company.

New Haven-based Arvinas Inc. announced it will work with Pfizer Inc. to find a third-party partner to commercialize their jointly developed breast cancer drug candidate.

A San Francisco investment firm has built a large stake in New Haven-based Arvinas Inc., and has been pressing for sweeping changes.

Arvinas Inc., a New Haven-based biotechnology company, said Wednesday that its CEO and president plans to retire once a successor is found.